Multiple myeloma chemotherapy has no effect but the proportion of plasma cells increased, it is considered that there is resistance to the chemotherapeutic drugs used, it is recommended to change the chemotherapy regimen.
Multiple myeloma is a malignant disease characterized by abnormal proliferation of clonal plasma cells, and the treatment of multiple myeloma has been continuously improved and perfected with the introduction of new drugs.
Currently, the main drugs used in the treatment of multiple myeloma are proteasome inhibitors (e.g., bortezomib, isazomib, etc.), immunomodulators (thalidomide, lenalidomide, pomalidomide, etc.), and glucocorticoids (dexamethasone) in combination with triple-agent chemotherapy, which has a remission rate of more than 70%.
If the patient’s symptoms and signs do not improve, and the plasma tumor cells in the bone marrow continue to rise, it is considered that there is drug resistance, and it is recommended to change the treatment regimen, such as mafranil, daltuzumab, CART cell therapy, etc.. Specific treatment modalities and drug selection should be made under the guidance of a specialist.